The Food and Drug Administration (FDA) has approved Baqsimi (glucagon; Eli Lilly) nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and older. The Food and ...

Nasal glucagon is seen as a game-changing delivery method to replace the multistep system of mixing powder and liquid with a simple, 1-step spray. The FDA Wednesday approved Eli Lilly & Co.’s nasal ...

(HealthDay News) — Nasal glucagon can effectively and efficiently manage moderate or severe hypoglycemic episodes (HEs) in real-world settings in adult patients with type 1 diabetes, according to a ...

The US Food and Drug Administration (FDA) has approved the first nasally administered glucagon product (Baqsimi, Eli Lilly and Co) for the treatment of severe hypoglycemia for patients aged 4 years or ...

TORONTO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Eli Lilly Canada is pleased to announce the approval and availability of a new rescue treatment for severe hypoglycemia, demonstrating Lilly’s commitment to ...

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an ...

BERLIN — An investigational nasal glucagon offers the potential for an easier-to-use alternative to the injected version of the hypoglycemia rescue medication, new data suggest. Findings from a ...

Eli Lilly this week announced it has submitted applications to US and European regulatory agencies for nasal glucagon, which, if approved, could shave minutes and stress from the current method for ...